198 related articles for article (PubMed ID: 18949060)
21. Proliferation-Independent Initiation of Biliary Cysts in Polycystic Liver Diseases.
Beaudry JB; Cordi S; Demarez C; Lepreux S; Pierreux CE; Lemaigre FP
PLoS One; 2015; 10(6):e0132295. PubMed ID: 26125584
[TBL] [Abstract][Full Text] [Related]
22. Liver cysts in Congolese patients with autosomal dominant polycystic kidney disease follow a family pattern.
Assounga AG; Yacoubou Y; Makosso E; Ibara JR; Gombet T
S Afr Med J; 2003 Jul; 93(7):542-4. PubMed ID: 12939930
[TBL] [Abstract][Full Text] [Related]
23. The spectrum of polycystic kidney disease in children.
Dell KM
Adv Chronic Kidney Dis; 2011 Sep; 18(5):339-47. PubMed ID: 21896375
[TBL] [Abstract][Full Text] [Related]
24. Identifying cystogenic paracrine signaling molecules in cyst fluid of patients with polycystic kidney disease.
Kenter AT; van Rossum-Fikkert SE; Salih M; Verhagen PCMS; van Leenders GJLH; Demmers JAA; Jansen G; Gribnau J; Zietse R; Hoorn EJ
Am J Physiol Renal Physiol; 2019 Jan; 316(1):F204-F213. PubMed ID: 30403162
[TBL] [Abstract][Full Text] [Related]
25. Hippo signaling-a central player in cystic kidney disease?
Müller RU; Schermer B
Pediatr Nephrol; 2020 Jul; 35(7):1143-1152. PubMed ID: 31297585
[TBL] [Abstract][Full Text] [Related]
26. Altered Hippo signalling in polycystic kidney disease.
Happé H; van der Wal AM; Leonhard WN; Kunnen SJ; Breuning MH; de Heer E; Peters DJ
J Pathol; 2011 May; 224(1):133-42. PubMed ID: 21381034
[TBL] [Abstract][Full Text] [Related]
27. Pathophysiology of childhood polycystic kidney diseases: new insights into disease-specific therapy.
Sweeney WE; Avner ED
Pediatr Res; 2014 Jan; 75(1-2):148-57. PubMed ID: 24336431
[TBL] [Abstract][Full Text] [Related]
28. Somatic mutation in individual liver cysts supports a two-hit model of cystogenesis in autosomal dominant polycystic kidney disease.
Watnick TJ; Torres VE; Gandolph MA; Qian F; Onuchic LF; Klinger KW; Landes G; Germino GG
Mol Cell; 1998 Aug; 2(2):247-51. PubMed ID: 9734362
[TBL] [Abstract][Full Text] [Related]
29. [Cystic liver diseases. Genetics and cell biology].
Housset C
Gastroenterol Clin Biol; 2005; 29(8-9):861-9. PubMed ID: 16294159
[TBL] [Abstract][Full Text] [Related]
30. Biliary dysgenesis in the PCK rat, an orthologous model of autosomal recessive polycystic kidney disease.
Masyuk TV; Huang BQ; Masyuk AI; Ritman EL; Torres VE; Wang X; Harris PC; Larusso NF
Am J Pathol; 2004 Nov; 165(5):1719-30. PubMed ID: 15509540
[TBL] [Abstract][Full Text] [Related]
31. Early cyst growth is associated with the increased nuclear expression of cyclin D1/Rb protein in an autosomal-recessive polycystic kidney disease rat model.
Schwensen KG; Burgess JS; Graf NS; Alexander SI; Harris DC; Phillips JK; Rangan GK
Nephron Exp Nephrol; 2011; 117(4):e93-103. PubMed ID: 20924203
[TBL] [Abstract][Full Text] [Related]
32. TGR5 contributes to hepatic cystogenesis in rodents with polycystic liver diseases through cyclic adenosine monophosphate/Gαs signaling.
Masyuk TV; Masyuk AI; Lorenzo Pisarello M; Howard BN; Huang BQ; Lee PY; Fung X; Sergienko E; Ardecky RJ; Chung TDY; Pinkerton AB; LaRusso NF
Hepatology; 2017 Oct; 66(4):1197-1218. PubMed ID: 28543567
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of MiR-199a-5p reduced cell proliferation in autosomal dominant polycystic kidney disease through targeting CDKN1C.
Sun L; Zhu J; Wu M; Sun H; Zhou C; Fu L; Xu C; Mei C
Med Sci Monit; 2015 Jan; 21():195-200. PubMed ID: 25588980
[TBL] [Abstract][Full Text] [Related]
34. Predictors of progression in autosomal dominant and autosomal recessive polycystic kidney disease.
Benz EG; Hartung EA
Pediatr Nephrol; 2021 Sep; 36(9):2639-2658. PubMed ID: 33474686
[TBL] [Abstract][Full Text] [Related]
35. Centrosomal abnormalities characterize human and rodent cystic cholangiocytes and are associated with Cdc25A overexpression.
Masyuk TV; Lee SO; Radtke BN; Stroope AJ; Huang B; Banales JM; Masyuk AI; Splinter PL; Gradilone SA; Gajdos GB; LaRusso NF
Am J Pathol; 2014 Jan; 184(1):110-21. PubMed ID: 24211536
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic Targets in Polycystic Liver Disease.
Masyuk TV; Masyuk AI; LaRusso NF
Curr Drug Targets; 2017; 18(8):950-957. PubMed ID: 25915482
[TBL] [Abstract][Full Text] [Related]
37. [Investigation of the gene locus in autosomal polycystic kidney disease in a 21 year old female patient with congenital hepatic fibrosis and polycystic liver].
Kosztolányi S; Gasztonyi B; Vincze A; Battyány I; Hegedús G; Czakó M; Pár A; Mózsik G
Orv Hetil; 2002 Nov; 143(46):2593-6. PubMed ID: 12520854
[TBL] [Abstract][Full Text] [Related]
38. Differential rescue of the renal and hepatic disease in an autosomal recessive polycystic kidney disease mouse mutant. A new model to study the liver lesion.
Yoder BK; Richards WG; Sommardahl C; Sweeney WE; Michaud EJ; Wilkinson JE; Avner ED; Woychik RP
Am J Pathol; 1997 Jun; 150(6):2231-41. PubMed ID: 9176412
[TBL] [Abstract][Full Text] [Related]
39. Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells.
Belibi FA; Reif G; Wallace DP; Yamaguchi T; Olsen L; Li H; Helmkamp GM; Grantham JJ
Kidney Int; 2004 Sep; 66(3):964-73. PubMed ID: 15327388
[TBL] [Abstract][Full Text] [Related]
40. Protein composition of liver cyst fluid from the BALB/c-cpk/+ mouse model of autosomal recessive polycystic kidney disease.
Lai X; Blazer-Yost BL; Gattone VH; Muchatuta MN; Witzmann FA
Proteomics; 2009 Jul; 9(14):3775-82. PubMed ID: 19639592
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
